Hospital
Variety Children's Hospital
Variety Children's Hospital was paid $175.32M by Medicaid between Jan 2018 and Dec 2023, across 428 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoVARIETY CHILDREN'S HOSPITAL
MIAMI, FL 33155
MIAMI, FL 33155
33aNPI1871540237assigned 05/30/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$175.32M
24GClaims1,625,065
24DCodes billed428
24AFirst – last monthJan 2018 – Dec 2023
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#1 of 163
Median peer was paid$4.77M
This provider vs. median37×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 55,873 | $4.93M | |
| 2019 | 456,512 | $46.37M | |
| 2020 | 268,359 | $23.34M | |
| 2021 | 387,102 | $39.49M | |
| 2022 | 286,750 | $32.87M | |
| 2023 | 170,469 | $28.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 140,351 | 131,137 | $28.48M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 8.4% | 72,448 | 18,048 | $14.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.2% | 60,077 | 56,612 | $14.37M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 7.4% | 70,918 | 17,913 | $13.00M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.9% | 47,678 | 13,708 | $10.32M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 32,173 | 30,886 | $6.17M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.4% | 64,480 | 57,514 | $4.19M |
| G0378 | Hospital observation service, per hour | 2.2% | 28,258 | 14,253 | $3.78M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.9% | 5,664 | 5,515 | $3.34M |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.6% | 3,410 | 3,218 | $2.83M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 37,698 | 35,491 | $2.77M |
| 44970 | 1.5% | 947 | 890 | $2.69M |
416 more codes
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.5% | 14,550 | $2.68M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.4% | 2,038 | $2.41M |
| 99285 | Emergency room visit (most serious) | 1.3% | 12,878 | $2.26M |
| 99213 | Doctor's office visit, returning patient (routine) | 1.2% | 14,666 | $2.04M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 10,793 | $2.02M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 2,633 | $1.57M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25,546 | $1.44M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 4,792 | $1.39M |
| 76775 | <1% | 9,052 | $1.37M | |
| 92587 | <1% | 5,760 | $1.36M | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 15,306 | $1.36M |
| 92526 | <1% | 12,602 | $1.29M | |
| 72082 | <1% | 12,925 | $1.26M | |
| 84703 | <1% | 11,105 | $1.15M | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 7,289 | $1.14M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,038 | $1.12M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,761 | $1.12M |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 20,616 | $1.11M |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,682 | $1.02M |
| 92523 | <1% | 4,438 | $988K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 3,725 | $973K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,012 | $968K |
| 01922 | <1% | 5,612 | $814K | |
| 80053 | Comprehensive metabolic panel | <1% | 12,997 | $779K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,456 | $728K |
| 76536 | <1% | 4,251 | $716K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 2,448 | $702K |
| 77072 | <1% | 7,373 | $695K | |
| 73610 | <1% | 6,814 | $677K | |
| 95816 | <1% | 2,216 | $649K | |
| 97168 | <1% | 1,909 | $642K | |
| 95715 | <1% | 1,232 | $629K | |
| 73140 | <1% | 5,672 | $628K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 16,153 | $625K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,665 | $593K |
| C9399 | Unclassified drugs or biologicals | <1% | 5,989 | $591K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,397 | $575K |
| 97164 | <1% | 1,522 | $568K | |
| 95782 | <1% | 612 | $562K | |
| 73630 | <1% | 6,928 | $540K | |
| 97161 | <1% | 2,249 | $513K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,789 | $478K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,910 | $457K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,532 | $451K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,386 | $449K |
| 74455 | <1% | 857 | $448K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12,484 | $429K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,927 | $419K |
| 93976 | <1% | 2,608 | $408K | |
| 92610 | <1% | 1,591 | $408K | |
| 87070 | <1% | 12,517 | $399K | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 306 | $394K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,382 | $387K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 720 | $383K |
| 73090 | <1% | 6,296 | $374K | |
| 73130 | <1% | 4,403 | $368K | |
| 85027 | <1% | 30,958 | $364K | |
| 74019 | <1% | 6,525 | $331K | |
| 72170 | <1% | 3,975 | $330K | |
| 73100 | <1% | 3,786 | $327K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,157 | $325K |
| 76885 | <1% | 1,629 | $325K | |
| 73070 | <1% | 5,078 | $323K | |
| 80306 | <1% | 2,043 | $312K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 887 | $312K |
| 97116 | <1% | 3,807 | $306K | |
| 97162 | <1% | 932 | $304K | |
| 73110 | <1% | 3,837 | $298K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,279 | $288K |
| 74018 | <1% | 3,571 | $283K | |
| 81001 | <1% | 26,205 | $280K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,507 | $278K |
| 73590 | <1% | 3,678 | $277K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 21,903 | $275K |
| 76882 | <1% | 1,811 | $271K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,643 | $264K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 18,207 | $245K |
| 24640 | <1% | 516 | $245K | |
| 36430 | <1% | 529 | $244K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,932 | $241K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,277 | $231K |
| 80047 | <1% | 2,363 | $227K | |
| 73564 | <1% | 2,464 | $226K | |
| 97167 | <1% | 767 | $224K | |
| 76770 | <1% | 1,316 | $201K | |
| 12011 | <1% | 1,709 | $200K | |
| 73521 | <1% | 2,293 | $197K | |
| 96415 | <1% | 2,738 | $191K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,790 | $186K |
| 87807 | <1% | 11,906 | $184K | |
| 88312 | <1% | 2,529 | $184K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,915 | $182K |
| 82962 | <1% | 2,976 | $173K | |
| 73560 | <1% | 2,925 | $171K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,144 | $165K |
| 73000 | <1% | 1,807 | $162K | |
| 87045 | <1% | 2,471 | $162K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,487 | $161K |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 802 | $160K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,117 | $148K |
| 86140 | <1% | 12,520 | $146K | |
| 97166 | <1% | 457 | $146K | |
| 94664 | <1% | 10,481 | $145K | |
| 96450 | <1% | 259 | $138K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 851 | $136K |
| 76641 | <1% | 1,317 | $132K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 663 | $132K |
| 74240 | <1% | 703 | $128K | |
| 76506 | <1% | 766 | $127K | |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 57 | $125K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,186 | $125K |
| 82805 | <1% | 2,004 | $123K | |
| 97760 | <1% | 538 | $122K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,438 | $121K |
| 70360 | <1% | 1,936 | $118K | |
| 95819 | <1% | 337 | $111K | |
| 12001 | <1% | 904 | $107K | |
| 81003 | <1% | 2,205 | $106K | |
| 49452 | <1% | 191 | $102K | |
| 36000 | <1% | 1,231 | $101K | |
| 77073 | <1% | 1,000 | $100K | |
| 87507 | <1% | 1,656 | $99K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,799 | $97K |
| 74183 | <1% | 163 | $92K | |
| 84100 | <1% | 4,235 | $89K | |
| 73080 | <1% | 1,350 | $85K | |
| 73660 | <1% | 797 | $85K | |
| 73030 | <1% | 1,221 | $85K | |
| 73552 | <1% | 1,550 | $83K | |
| 72100 | <1% | 1,056 | $82K | |
| 64450 | <1% | 262 | $75K | |
| 96376 | <1% | 2,835 | $75K | |
| 82247 | <1% | 1,100 | $74K | |
| 95951 | <1% | 439 | $74K | |
| 97113 | <1% | 220 | $71K | |
| 92579 | <1% | 3,381 | $69K | |
| 80076 | <1% | 4,592 | $69K | |
| 82657 | <1% | 1,631 | $67K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 454 | $67K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,363 | $65K |
| 73060 | <1% | 938 | $65K | |
| 97163 | <1% | 170 | $64K | |
| 00140 | <1% | 229 | $62K | |
| 95822 | <1% | 1,058 | $58K | |
| 87077 | <1% | 5,411 | $57K | |
| 70220 | <1% | 565 | $57K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 80 | $57K |
| 82397 | <1% | 519 | $54K | |
| 43762 | <1% | 499 | $54K | |
| 76010 | <1% | 350 | $54K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 888 | $54K |
| 95700 | <1% | 1,227 | $53K | |
| 82728 | <1% | 1,125 | $52K | |
| 90999 | Dialysis (unlisted procedure) | <1% | 360 | $51K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 190 | $51K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 71 | $51K |
| 74241 | <1% | 299 | $51K | |
| 78700 | <1% | 99 | $49K | |
| 92588 | <1% | 418 | $49K | |
| 86665 | <1% | 1,097 | $45K | |
| 99205 | Prolong outpt/office vis | <1% | 1,708 | $45K |
| 83735 | <1% | 3,155 | $45K | |
| 88304 | <1% | 2,118 | $44K | |
| 70260 | <1% | 358 | $44K | |
| 76800 | <1% | 239 | $43K | |
| 92557 | <1% | 577 | $42K | |
| 01999 | <1% | 388 | $40K | |
| 93325 | <1% | 3,000 | $35K | |
| 82947 | <1% | 3,411 | $34K | |
| 82565 | <1% | 1,025 | $33K | |
| 96409 | <1% | 503 | $33K | |
| 84295 | <1% | 1,501 | $33K | |
| 77077 | <1% | 496 | $33K | |
| 73565 | <1% | 448 | $33K | |
| 84132 | <1% | 1,762 | $32K | |
| 69210 | <1% | 444 | $31K | |
| 83970 | <1% | 462 | $31K | |
| 89050 | <1% | 644 | $31K | |
| 76857 | <1% | 274 | $30K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,061 | $30K |
| 72146 | <1% | 197 | $29K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 786 | $29K |
| 73620 | <1% | 561 | $29K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 243 | $29K |
| 82550 | <1% | 2,411 | $28K | |
| 72040 | <1% | 443 | $28K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 160 | $28K |
| 85045 | <1% | 1,446 | $28K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 364 | $27K |
| 72197 | <1% | 132 | $26K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 7,796 | $26K |
| 36591 | <1% | 932 | $25K | |
| 74230 | <1% | 99 | $24K | |
| 83550 | <1% | 596 | $24K | |
| 83540 | <1% | 694 | $23K | |
| 00400 | <1% | 410 | $23K | |
| 97763 | <1% | 568 | $23K | |
| 70543 | <1% | 82 | $22K | |
| 85007 | <1% | 23,897 | $22K | |
| 29075 | <1% | 1,769 | $22K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,857 | $22K |
| 86850 | <1% | 2,050 | $21K | |
| 73221 | <1% | 83 | $21K | |
| 84439 | <1% | 2,561 | $21K | |
| 80061 | Lipid panel | <1% | 754 | $20K |
| 29065 | <1% | 1,410 | $20K | |
| 94010 | <1% | 226 | $19K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 26,306 | $18K |
| 29125 | <1% | 811 | $18K | |
| 88300 | <1% | 1,792 | $18K | |
| 29130 | <1% | 908 | $18K | |
| 87181 | <1% | 631 | $17K | |
| 54161 | <1% | 46 | $17K | |
| 85014 | <1% | 3,375 | $17K | |
| 84520 | <1% | 552 | $17K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 139 | $16K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 23,478 | $16K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 15,199 | $14K |
| 70486 | <1% | 122 | $14K | |
| 83615 | <1% | 1,936 | $14K | |
| 93226 | <1% | 305 | $14K | |
| 73700 | <1% | 55 | $13K | |
| 87040 | <1% | 6,107 | $13K | |
| 95716 | <1% | 14 | $13K | |
| 10060 | <1% | 168 | $13K | |
| 78262 | <1% | 25 | $13K | |
| 29405 | <1% | 972 | $12K | |
| 92552 | <1% | 655 | $12K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,057 | $12K |
| 69200 | <1% | 79 | $11K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,558 | $11K |
| 43760 | <1% | 38 | $11K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 10,433 | $10K |
| S9083 | Global fee urgent care centers | <1% | 431 | $10K |
| 76377 | <1% | 1,761 | $10K | |
| 97165 | <1% | 32 | $9K | |
| 25605 | <1% | 146 | $9K | |
| 86403 | <1% | 995 | $9K | |
| 92585 | <1% | 162 | $9K | |
| 72081 | <1% | 110 | $9K | |
| 76604 | <1% | 59 | $9K | |
| 00300 | <1% | 440 | $9K | |
| 87581 | <1% | 6,916 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,219 | $9K |
| 93308 | <1% | 13 | $8K | |
| 73562 | <1% | 107 | $8K | |
| 93320 | <1% | 2,543 | $8K | |
| 87102 | <1% | 228 | $8K | |
| 75565 | <1% | 30 | $8K | |
| 29105 | <1% | 344 | $8K | |
| 82150 | <1% | 1,010 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 675 | $8K |
| 76881 | <1% | 69 | $8K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 4,946 | $8K |
| J2704 | Injection, propofol, 10 mg | <1% | 10,110 | $7K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,951 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,572 | $7K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 218 | $7K |
| 72070 | <1% | 158 | $7K | |
| 87340 | <1% | 127 | $6K | |
| 92018 | <1% | 31 | $6K | |
| 87075 | <1% | 84 | $6K | |
| 94060 | <1% | 115 | $6K | |
| 51600 | <1% | 855 | $6K | |
| 72141 | <1% | 306 | $6K | |
| 84484 | <1% | 404 | $6K | |
| 00148 | <1% | 147 | $6K | |
| 94621 | <1% | 53 | $6K | |
| 83993 | <1% | 181 | $6K | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 5,422 | $6K |
| B4087 | Gastrostomy/jejunostomy tube, standard, any material, any type, each | <1% | 13 | $6K |
| 73600 | <1% | 71 | $5K | |
| 92555 | <1% | 553 | $5K | |
| 82310 | <1% | 276 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,210 | $5K |
| 93356 | <1% | 14 | $5K | |
| 87205 | <1% | 1,270 | $5K | |
| 86480 | <1% | 194 | $5K | |
| 87486 | <1% | 6,754 | $5K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 3,678 | $4K |
| 92652 | <1% | 83 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,353 | $4K |
| 10120 | <1% | 12 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 26 | $4K |
| 73718 | <1% | 15 | $4K | |
| 85610 | <1% | 1,850 | $4K | |
| 85652 | <1% | 4,281 | $4K | |
| 85730 | <1% | 1,668 | $4K | |
| 87186 | <1% | 4,533 | $4K | |
| 29515 | <1% | 967 | $4K | |
| C1769 | Guide wire | <1% | 67 | $4K |
| 82330 | <1% | 1,050 | $4K | |
| 76870 | <1% | 924 | $4K | |
| 92611 | <1% | 94 | $3K | |
| 78708 | <1% | 12 | $3K | |
| 86900 | <1% | 2,052 | $3K | |
| 92567 | <1% | 6,408 | $3K | |
| 92586 | <1% | 22 | $3K | |
| 86901 | <1% | 2,048 | $3K | |
| 88342 | <1% | 117 | $3K | |
| 12051 | <1% | 43 | $3K | |
| 83690 | <1% | 2,832 | $3K | |
| 82272 | <1% | 35 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 180 | $3K |
| 51701 | <1% | 414 | $3K | |
| 16020 | <1% | 13 | $3K | |
| 82784 | <1% | 1,847 | $2K | |
| 93886 | <1% | 15 | $2K | |
| 70546 | <1% | 18 | $2K | |
| 29505 | <1% | 445 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 6,555 | $2K |
| 83520 | <1% | 355 | $2K | |
| J3490 | Unclassified drugs | <1% | 4,008 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,426 | $2K |
| 88325 | <1% | 93 | $2K | |
| 86923 | <1% | 192 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 521 | $2K |
| 87641 | <1% | 55 | $2K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 6,233 | $2K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 4,616 | $2K |
| 64611 | <1% | 12 | $2K | |
| 69209 | <1% | 14 | $1K | |
| 86235 | <1% | 1,134 | $1K | |
| 92582 | <1% | 786 | $1K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 15 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 676 | $1K |
| 70250 | <1% | 25 | $1K | |
| 76510 | <1% | 28 | $961.41 | |
| 93225 | <1% | 305 | $923.03 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 725 | $852.19 |
| 00840 | <1% | 1,102 | $778.48 | |
| 92556 | <1% | 800 | $752.12 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 128 | $738.54 |
| 00920 | <1% | 341 | $734.60 | |
| 97542 | <1% | 14 | $665.73 | |
| 96523 | <1% | 20 | $650.34 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,192 | $622.39 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 1,169 | $618.43 |
| 72156 | <1% | 15 | $617.75 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 293 | $549.56 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 674 | $548.23 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 136 | $543.01 |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 465 | $495.39 |
| 92653 | <1% | 73 | $476.65 | |
| 92235 | <1% | 17 | $464.56 | |
| A9539 | Technetium tc-99m pentetate, diagnostic, per study dose, up to 25 millicuries | <1% | 381 | $454.27 |
| 82785 | <1% | 12 | $404.84 | |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 105 | $390.88 |
| 00731 | <1% | 603 | $390.22 | |
| 83605 | <1% | 516 | $371.66 | |
| 88302 | <1% | 13 | $305.07 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 356 | $298.68 |
| 88341 | <1% | 13 | $297.94 | |
| 29086 | <1% | 13 | $290.01 | |
| 87177 | <1% | 92 | $278.31 | |
| 88346 | <1% | 172 | $254.35 | |
| 84145 | <1% | 506 | $251.54 | |
| 87427 | <1% | 1,161 | $235.94 | |
| 92250 | <1% | 30 | $192.18 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 278 | $187.68 |
| 82248 | <1% | 86 | $168.70 | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 416 | $147.05 |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,099 | $100.34 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 128 | $96.90 |
| 76942 | <1% | 85 | $94.08 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 381 | $90.45 |
| 80051 | <1% | 46 | $89.48 | |
| 80349 | <1% | 107 | $88.36 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 31 | $87.60 |
| 82977 | <1% | 105 | $83.66 | |
| 88108 | <1% | 329 | $82.32 | |
| 85379 | <1% | 64 | $76.99 | |
| 82533 | <1% | 27 | $72.47 | |
| 87497 | <1% | 126 | $52.61 | |
| 87640 | <1% | 39 | $45.92 | |
| 01400 | <1% | 34 | $44.62 | |
| 00160 | <1% | 151 | $43.74 | |
| 84550 | <1% | 42 | $35.60 | |
| 87209 | <1% | 16 | $23.52 | |
| 00126 | <1% | 139 | $23.52 | |
| 94760 | <1% | 14 | $22.20 | |
| 82607 | <1% | 14 | $19.82 | |
| 87305 | <1% | 88 | $18.72 | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 64 | $11.76 |
| 96367 | <1% | 223 | $11.76 | |
| 94799 | <1% | 28 | $11.76 | |
| 84436 | <1% | 12 | $11.10 | |
| 82374 | <1% | 22 | $0.01 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 53 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,268 | $0.00 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 0% | 1,795 | $0.00 |
| 76937 | 0% | 27 | $0.00 | |
| 87338 | 0% | 14 | $0.00 | |
| 94642 | 0% | 12 | $0.00 | |
| 00635 | 0% | 35 | $0.00 | |
| A9551 | Technetium tc-99m succimer, diagnostic, per study dose, up to 10 millicuries | 0% | 43 | $0.00 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 13 | $0.00 |
| 83516 | 0% | 12 | $0.00 | |
| 82010 | 0% | 12 | $0.00 | |
| 29345 | 0% | 105 | $0.00 | |
| 86160 | 0% | 26 | $0.00 | |
| 49465 | 0% | 26 | $0.00 | |
| 96411 | 0% | 80 | $0.00 | |
| 72158 | 0% | 15 | $0.00 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 0% | 82 | $0.00 |
| 86920 | 0% | 13 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 116 | $0.00 |
| 00813 | 0% | 12 | $0.00 | |
| 96368 | 0% | 43 | $0.00 | |
| J9250 | Methotrexate sodium, 5 mg | 0% | 39 | $0.00 |
| J0713 | Injection, ceftazidime, per 500 mg | 0% | 15 | $0.00 |
| 30802 | 0% | 28 | $0.00 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 16 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 27 | $0.00 |
| 81382 | 0% | 12 | $0.00 | |
| 83880 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLOVE, MATTHEW (CEO)
| Provider | Location | Paid |
|---|---|---|
| Miami Children's Hospital | Doral, FL | $8.05M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.